Iain R Murray, Jorge Chahla, Sarah J Wordie, Shane A Shapiro, Nicolas S Piuzzi, Rachel M Frank, Joanne Halbrecht, Kiyoshi Okada, Norimasa Nakamura, Bert Mandelbaum, Jason L Dragoo, Joanne Borg-Stein, Adam Anz, Alberto Gobbi, Andreas H Gomoll, Brian J Cole, Christian Lattermann, Constance Chu, Daniel A Grande, Daniel B F Saris, David Flanigan, Elizaveta Kon, George F Muschler, Gerard A Malanga, Greg Dummer, Jack Farr, John M Tokish, Kurt P Spindler, Kay Horsch, Ken Zaslav, Louis F McIntyre, Nicholas A Sgaglione, Seth L Sherman, Scott Rodeo, Tariq M Awan, C Thomas Vangsness
Orthobiologic therapies show significant promise to improve outcomes for patients with musculoskeletal pathology. There are considerable research efforts to develop strategies that seek to modulate the biological environment to promote tissue regeneration and healing and/or provide symptomatic relief. However, the regulatory pathways overseeing the clinical translation of these therapies are complex, with considerable worldwide variation. The introduction of novel biologic treatments into clinical practice raises several ethical dilemmas...
November 2022: Orthopaedic Journal of Sports Medicine